Candel Therapeutics, Inc. (CADL)
Market Cap | 185.98M |
Revenue (ttm) | n/a |
Net Income (ttm) | -37.37M |
Shares Out | 29.76M |
EPS (ttm) | -1.28 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 517,904 |
Open | 6.14 |
Previous Close | 6.30 |
Day's Range | 6.08 - 6.54 |
52-Week Range | 0.66 - 14.30 |
Beta | -0.83 |
Analysts | Strong Buy |
Price Target | 11.00 (+76.0%) |
Earnings Date | Aug 8, 2024 |
About CADL
Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. It develops CAN-2409, which is in Phase II clinical trials for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma. The company also develops CAN-3110, which is in Phase I clinical trials for the treatment of... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to one analyst, the rating for CADL stock is "Strong Buy" and the 12-month stock price forecast is $11.0.
News
![](https://cdn.snapi.dev/images/v1/r/d/press1-2473039.jpg)
Candel Therapeutics to Join Russell 3000® Index
NEEDHAM, Mass., June 11, 2024 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal biologic...
![](https://cdn.snapi.dev/images/v1/j/0/press2-2453473.jpg)
FDA Grants Orphan Drug Designation for CAN-3110 for the Treatment of Recurrent High-Grade Glioma
NEEDHAM, Mass., May 30, 2024 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal biologica...
![](https://cdn.snapi.dev/images/v1/t/u/press11-2446488.jpg)
Candel Therapeutics Reports Prolonged Overall Survival in Phase 2 Clinical Trial of CAN-2409 for Advanced Non-Small Cell Lung Cancer (NSCLC) in Patients Non-Responsive to Immune Checkpoint Inhibitor (ICI) Treatment at 2024 ASCO Annual Meeting
NEEDHAM, Mass., May 23, 2024 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal biologica...
![](https://cdn.snapi.dev/images/v1/h/s/conf12-2443214.jpg)
Candel Therapeutics to Present at the Jefferies Global Healthcare Conference
NEEDHAM, Mass., May 22, 2024 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal biologica...
![](https://cdn.snapi.dev/images/v1/j/0/press16-2439417.jpg)
Candel Therapeutics to Host Non-Small Cell Lung Cancer (NSCLC) R&D Breakfast Panel During 2024 ASCO Annual Meeting
Management and scientific/medical thought leaders to discuss topline overall survival data from phase 2 clinical trial of CAN-2409 in NSCLC Management and scientific/medical thought leaders to discuss...
![](https://cdn.snapi.dev/images/v1/m/i/press12-2429159.jpg)
Candel Therapeutics Reports First Quarter 2024 Financial Results and Recent Corporate Highlights
NEEDHAM, Mass., May 14, 2024 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal biologica...
![](https://cdn.snapi.dev/images/v1/a/c/press12-2390854.jpg)
Candel Therapeutics Announces Upcoming Presentations at the 2024 ASCO Annual Meeting
NEEDHAM, Mass., April 25, 2024 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal biologi...
![](https://cdn.snapi.dev/images/v1/y/e/press20-2367203.jpg)
Candel Therapeutics Receives FDA Orphan Drug Designation for CAN-2409 for the Treatment of Pancreatic Cancer
NEEDHAM, Mass., April 11, 2024 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal biologi...
![](https://cdn.snapi.dev/images/v1/t/7/press8-2362798.jpg)
Candel Therapeutics Presents Preclinical Data at AACR on Immunotherapy Candidate for Induction of Tertiary Lymphoid Structures in Solid Tumors
NEEDHAM, Mass., April 09, 2024 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal biologi...
![](https://cdn.snapi.dev/images/v1/c/9/im-21777162size177777777777777-2358517.jpg)
Candel Therapeutics stock jumps as pancreatic cancer treatment shows promise
Shares of Candel Therapeutics Inc. CADL, +280.95% climbed 15% early Friday after the company released new data from a trial of its experimental cancer treatment.
![](https://cdn.snapi.dev/images/v1/h/e/68568174-m-normal-none-2358494.jpg)
Candel Therapeutics stock soars 30%: find out more
Candel Therapeutics Inc is up roughly 30% in premarket on Friday after reporting positive interim data for its experimental treatment of non-metastatic pancreatic cancer. CAN-2409 data sends Candel Th...
![](https://cdn.snapi.dev/images/v1/o/a/press20-2356206.jpg)
Candel Therapeutics Announces Positive Interim Data from Randomized Phase 2 Clinical Trial of CAN-2409 in Non-Metastatic Pancreatic Cancer
NEEDHAM, Mass., April 04, 2024 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal biologi...
![](https://cdn.snapi.dev/images/v1/q/b/press6-2347168.jpg)
Candel Therapeutics Announces Oral Presentation During the 5th Glioblastoma Drug Development Summit with Update on Phase 1b Clinical Trial of CAN-3110 in Recurrent High-Grade Glioma
NEEDHAM, Mass., March 28, 2024 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing and commercializin...
![](https://cdn.snapi.dev/images/v1/b/m/press10-2346008.jpg)
Candel Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Highlights
NEEDHAM, Mass., March 28, 2024 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal biologi...
![](https://cdn.snapi.dev/images/v1/p/r/press6-2310789.jpg)
Biotech/Oncology Stocks Targeting the Pancreatic Cancer Market - A Race Worth Winning
Vancouver, Kelowna and Delta, British Columbia--(Newsfile Corp. - March 6, 2024) - Investorideas.com, a global investor news source covering biotech and pharma stocks issues a sector snapshot on devel...
![](https://cdn.snapi.dev/images/v1/7/n/press3-2309680.jpg)
Candel Therapeutics Announces an Upcoming Presentation at the AACR Annual Meeting Unveiling New Cancer Immunotherapy Candidate
NEEDHAM, Mass., March 05, 2024 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal biologi...
![](https://cdn.snapi.dev/images/v1/q/s/press19-2273120.jpg)
CAN-3110 Receives FDA Fast Track Designation for Treatment of Recurrent High-Grade Glioma
NEEDHAM, Mass., Feb. 13, 2024 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal biologic...
![](https://cdn.snapi.dev/images/v1/x/v/press14-2259647.jpg)
Candel Therapeutics Sets Path to Success: Recent Achievements Pave the Way for a Promising 2024 Propelled by Key Value Drivers and Catalysts
Approaching 6 anticipated data readouts across 3 platforms in 2024, including survival data in non-small cell lung cancer (NSCLC) and a potentially registrational phase 3 clinical trial in prostate ca...
![](https://cdn.snapi.dev/images/v1/y/e/press18-2192645.jpg)
Candel Therapeutics Receives FDA Fast Track Designation for CAN-2409 in Pancreatic Cancer
NEEDHAM, Mass., Dec. 12, 2023 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal biologic...
![](https://cdn.snapi.dev/images/v1/u/h/press16-2173889.jpg)
Candel Therapeutics Announces Restructuring to Prioritize Resources on Key Value Drivers for Expanded Development of CAN-3110, the enLIGHTEN™ Discovery Platform, and Key Clinical Readouts for CAN-2409
NEEDHAM, Mass., Nov. 28, 2023 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal biologic...
![](https://cdn.snapi.dev/images/v1/s/t/press11-2149510.jpg)
Candel Therapeutics Reports Third Quarter 2023 Financial Results and Recent Corporate Highlights
NEEDHAM, Mass., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing viral immunotherapi...
![](https://cdn.snapi.dev/images/v1/f/y/press2-2140409.jpg)
Candel Therapeutics Presents Preclinical Data from its enLIGHTEN™ Discovery Platform at SITC
NEEDHAM, Mass., Nov. 04, 2023 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (the Company or Candel) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing viral immunotherapi...
![](https://cdn.snapi.dev/images/v1/9/w/press4-2139433.jpg)
Candel Therapeutics Announces Initial Positive Interim Data from Randomized Phase 2 Clinical Trial of CAN-2409 in Non-Metastatic Pancreatic Cancer
NEEDHAM, Mass., Nov. 03, 2023 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing viral immunotherapi...
![](https://cdn.snapi.dev/images/v1/k/e/press19-2109112.jpg)
Candel Therapeutics Announces Nature Publication Showing Extended Survival Associated with Immune Activation in Patients with Recurrent High-Grade Glioma Treated with CAN-3110
NEEDHAM, Mass., Oct. 18, 2023 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (the Company or Candel) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing viral immunotherapi...
![](https://cdn.snapi.dev/images/v1/s/p/press1-2079921.jpg)
Candel Therapeutics Announces Three Abstracts Accepted for Poster Presentations at SITC 2023 Annual Meeting
NEEDHAM, Mass., Sept. 27, 2023 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing and commercializing viral immunotherapies ...